Full-Time

Chemistry Account Manager

Deadline 6/16/27
Waters Corporation

Waters Corporation

10,001+ employees

Analytical instruments, software, and services provider

No salary listed

Cambridge, MA, USA

In Person

Category
Sales & Account Management
Required Skills
Sales

Get referred to Waters Corporation

Find people who can refer or advise you

Requirements
  • Minimum of BS/BA in chemistry or a related discipline
  • At least 3 years LC and/or LC/MS experience.
  • Practical sales experience is an advantage
  • Action oriented and self-driven for results
  • Excellent communication and presentation skills
  • Excellent organization / planning / time management skills
  • Strong interpersonal skills and a good listener
  • Mature disposition, positive attitude and strong sense of commitment
  • Adaptive to dynamic and changing environment
Responsibilities
  • Meet or exceed sales targets
  • Maintain and grow installed base customer satisfaction
  • Aggressively develop new prospects and penetrate competitive accounts
  • Visit customers and prospects on a daily basis to understand needs and challenges and highlight Waters solutions
  • Build technical competency on Waters solution and be perceived by customers as a valued business partner
  • Keep current on market dynamics, application trends, and competitive landscape
  • Become an active member of the local scientific community to understand customer needs and promote Waters solutions
  • Provide feedback to marketing team to create business development programs
  • Fully utilize sales contact management tools and applications
  • Submit accurate and timely monthly sales forecasts

Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.

Company Size

10,001+

Company Stage

IPO

Headquarters

Milford, Connecticut

Founded

1958

Get referred to Waters Corporation

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The SNT Biotech partnership addresses 60% of unscreened cervical cancer cases with insurer coverage starting 2027.
  • IMU Biosciences collaboration uses Waters instruments to analyze 100M+ immune data points for precision cancer medicine.
  • New BioResolve and GTxResolve columns deliver 3x faster GLP-1 characterization and 2x faster LNP analysis since June 2026.

What critics are saying

  • Execution failure in merging BD Biosciences ($17.5B) into Waters could cause operational chaos and margin erosion below 11%.
  • Johnson & Johnson and AbbVie may erode Waters' HPV screening advantage by capturing 15-20% of the market within 24 months.
  • Chinese rivals like Enovix could undercut the $1.45B Coin Cell DSC segment, risking 20% revenue miss in battery QA/QC.

What makes Waters Corporation unique

  • Waters integrates BD flow cytometry with its analytical platforms for end-to-end life science solutions.
  • Its FDA-cleared Onclarity HPV kit enables at-home cervical cancer screening covering 14 high-risk genotypes.
  • Waters Coin Cell DSC tests intact battery cells without teardown, reducing prep time by over 90%.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

16%

1 year growth

16%

2 year growth

14%
PR Newswire
Apr 14th, 2026
Waters launches omniDAWN MALS detector for UHPLC, enabling 4x faster analysis of large molecules

Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.

PR Newswire
Apr 8th, 2026
Waters gains FDA clearance for at-home cervical cancer screening kit with HPV assay

Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.

Paul Hastings LLP
Mar 23rd, 2026
Waters Corporation subsidiary raises $3.5B through senior notes offering

Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.

Yahoo Finance
Mar 19th, 2026
Waters Corporation stock down 22.8% year-on-year, underperforming Dow's 11.2% rise

Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.

Yahoo Finance
Mar 17th, 2026
Waters Corporation Q4 results mixed as research tools sector faces 20.9% share price decline

Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.